GlobeNewswire·Jan 7, 2026, 8:00 AM ET

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB Biotherapeutics, Inc. appointed David Zaccardelli, Pharm.D., as Chair of the Board of Directors effective immediately.
The company appointed Rita Jain, M.D., as an Independent Director effective immediately.
David Zaccardelli brings over 20 years of experience leading companies from clinical to commercial stages, including recent leadership at Verona Pharma where he launched Ohtuvayre®.
Rita Jain is a rheumatologist with over two decades of experience in biopharmaceutical development, most recently serving as Executive Vice President and Chief Medical Officer at ChemoCentryx.
CEO Samuel J. Reich stated the new appointments underscore SAB's growth trajectory & validate its strategic direction for advancing SAB-142.
SAB-142 is a clinical-stage candidate targeting autoimmune Type 1 Diabetes (T1D) using a proprietary transchromosomic bovine (Tc-Bovine™) technology to produce human immunoglobulin G.
The company plans to advance SAB-142 through registrational clinical trials with the goal of delaying onset & preventing disease progression in Stage 3 T1D patients.
Dr. Zaccardelli expressed his intent to partner with management to guide the company through clinical development & potential commercialization.
Dr. Jain expressed excitement to join the board as the company advances its therapy that may transform treatment for T1D & other autoimmune diseases.